Annual report pursuant to Section 13 and 15(d)

SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)

v3.22.4
SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 24 Months Ended
Jan. 31, 2023
Feb. 28, 2021
Jan. 31, 2021
Oct. 31, 2020
Feb. 29, 2020
Oct. 31, 2019
Jan. 31, 2019
Oct. 31, 2018
Mar. 31, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2022
Collaborations                          
Upfront payment received                     $ 125,000    
Financing liability with accreted interest expense                     60,700    
Accretion expense                   $ 700 2,800    
Payment of cost share to collaboration partner                   15,116      
Accounts receivable                   40,320 15,472   $ 40,320
Research and development                   60,272 65,237 $ 60,101  
Intangible asset                   14,949     14,949
Accounts payable                   22,508 3,795   22,508
Collaborative Arrangement [Member]                          
Collaborations                          
Contingent payments                   1,300,000      
License agreement with unrelated third party                          
Collaborations                          
Revenue recognized                     4,000    
Proceeds from License Fees Received   $ 4,000                      
One-time fee received from license rights granted   $ 4,000                      
Specified Development Events [Member] | Collaborative Arrangement [Member]                          
Collaborations                          
Contingent payments                   279,500      
Specified Regulatory Events [Member] | Collaborative Arrangement [Member]                          
Collaborations                          
Contingent payments                   263,100      
Specified Product Launch Events [Member] | Collaborative Arrangement [Member]                          
Collaborations                          
Contingent payments                   796,000      
Development and regulatory milestones by non-CNS disease products                          
Collaborations                          
Contingent payments                   330,000      
Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis                          
Collaborations                          
Contingent payments                   100,000      
Development and regulatory milestones by CNS disease products                          
Collaborations                          
Contingent payments                   255,000      
Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis                          
Collaborations                          
Contingent payments                   150,000      
Delivery of drug supply for commercialization                          
Collaborations                          
Revenue recognized                   200      
Grifols                          
Collaborations                          
Contingent payments                   277,500      
Upfront payment received       $ 30,000     $ 30,000            
Revenue recognized                 $ 20,000        
Nonrefundable upfront payment       $ 5,000                  
Revenue, cumulative catch-up                 $ 25,000        
Grifols | Licensed Rights                          
Collaborations                          
Revenue recognized                       39,900  
Grifols | Delivery of drug supply for commercialization                          
Collaborations                          
Revenue recognized                   1,600 2,000 700  
Grifols | Exercise of option to include additional territories                          
Collaborations                          
Revenue recognized                       500  
Grifols | Commercial milestones                          
Collaborations                          
Contingent payments             $ 297,500            
Kissei                          
Collaborations                          
Contingent payments               $ 147,000          
Upfront payment received               33,000          
Revenue, remaining performance obligation               $ 33,000          
Revenue recognized                   2,600 300 0  
Deferred revenue                   1,400 1,400   1,400
Knight | Commercial and license agreements                          
Collaborations                          
Upfront payment received                   $ 2,000      
Knight | Minimum | Commercial and license agreements                          
Collaborations                          
Royalty payment as a percentage of net sales                   20.00%      
Knight | Maximum | Commercial and license agreements                          
Collaborations                          
Contingent payments                   $ 20,000      
Royalty payment as a percentage of net sales                   30.00%      
Daiichi Sankyo [Member] | Collaborative Arrangement [Member]                          
Collaborations                          
Revenue recognized                     1,800 2,100  
Forma                          
Collaborations                          
Upfront fee                   $ 2,000      
Research and development                   2,000      
Forma | Commercial milestones                          
Collaborations                          
Potential payments                   165,500      
Forma | Development and regulatory milestones                          
Collaborations                          
Potential payments                   67,500      
Forma | Achievement of certain near-term regulatory milestone.                          
Collaborations                          
Potential payments                   2,500      
Research and development                   2,500      
Forma | First regulatory approval of licensed product                          
Collaborations                          
Potential payments                   5,000      
Forma | Licensed product's first commercial sale subject to certain other conditions                          
Collaborations                          
Potential payments                   10,000      
fostamatinib                          
Collaborations                          
Revenue recognized                   4,500 10,500   15,000
Government contract     $ 16,500                    
Remaining amount of government award expected to be received in succeeding periods                   $ 1,500      
fostamatinib | Maximum                          
Collaborations                          
Government contract     $ 16,500                    
fostamatinib | Grifols                          
Collaborations                          
Collaborative payment received         $ 20,000                
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                          
Collaborations                          
Collaborative payment received         17,500                
fostamatinib | Grifols | Creditable advance royalty payment                          
Collaborations                          
Collaborative payment received         $ 2,500                
fostamatinib | Grifols | Maximum                          
Collaborations                          
Royalty payment as a percentage of net sales                   30.00%      
fostamatinib | Kissei                          
Collaborations                          
Revenue recognized                   $ 5,000      
Collaborative payment received                   5,000      
Accounts receivable                   20,000     20,000
fostamatinib | Medison | Financing arrangement                          
Collaborations                          
Upfront payment received           $ 5,000              
Financing liability with accreted interest expense                   0 5,600   0
Accretion expense                   0 400 0  
Revenue recognized                   $ 5,700      
fostamatinib | Medison | Commercial and license agreements                          
Collaborations                          
Revenue recognized                     100    
R552                          
Collaborations                          
Company's percentage of development costs                   20.00%      
Financing component liability                   $ 57,900     57,900
Financing liability interest accretion discount rate                   6.40%      
Financing liability with accreted interest expense                   $ 46,200     46,200
Payment of cost share to collaboration partner                   15,100      
Revenue, remaining performance obligation                     67,100    
R552 | Maximum                          
Collaborations                          
Funding commitment                   65,000     65,000
Non-CNS penetrant IP                          
Collaborations                          
Revenue recognized                     60,400    
Non-CNS penetrant IP | Licensed Rights                          
Collaborations                          
Revenue, remaining performance obligation                     6,700    
CNS penetrant IP                          
Collaborations                          
Revenue recognized                   500 6,200    
Research and development services | Grifols                          
Collaborations                          
Revenue recognized                   700 900 3,800  
Royalty | Grifols                          
Collaborations                          
Revenue recognized                   700 $ 0 $ 0  
REZLIDHIA | FDA approval and first commercial sale of product                          
Collaborations                          
Intangible asset                   15,000     15,000
Accounts payable                   $ 15,000     $ 15,000
Subsequent event | fostamatinib | Kissei                          
Collaborations                          
Revenue recognized $ 20,000